Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A

Journal of Medicinal Chemistry

Volumn 57, Issue 11, 2014, Pages 4629-4639

  Kolocouris, Antonios ^a   Tzitzoglaki, Christina ^a   Johnson, F Brent ^b   Zell, Roland ^c   Wright, Anna K ^d   Cross, Timothy A ^d   Tietjen, Ian ^e   Fedida, David ^e   Busath, David D ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b BRIGHAM YOUNG UNIVERSITY   (United States)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d FLORIDA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE DERIVATIVE; RIMANTADINE DERIVATIVE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG BINDING; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROPHYSIOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ADAMANTANE; AMANTADINE; ANIMALS; ANTIVIRAL AGENTS; DOGS; DRUG RESISTANCE, MULTIPLE, VIRAL; HEK293 CELLS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; ION CHANNELS; MADIN DARBY CANINE KIDNEY CELLS; MUTATION; RIMANTADINE; VIRAL MATRIX PROTEINS;

EID: 84902455679     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500598u     Document Type: Article

References (47)

1. Bright, R. A.; Medina, M. J.; Xu, X.; Perez-Oronoz, G.; Wallis, T. R.; Davis, X. M.; Povinelli, L.; Cox, N. J.; Klimov, A. I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern Lancet 2005, 366, 1175-1181 (Pubitemid 41393595)
2. Bright, R. A.; Shay, D. K.; Shu, B.; Cox, N. J.; Klimov, A. I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States JAMA, J. Am. Med. Assoc. 2006, 295, 891-894
3. Lan, Y.; Zhang, Y.; Dong, L.; Wang, D.; Huang, W.; Xin, L.; Yang, L.; Zhao, X.; Li, Z.; Wang, W.; Li, X.; Xu, C.; Guo, J.; Wang, M.; Peng, Y.; Gao, Y.; Guo, Y.; Wen, L.; Jiang, T.; Shu, Y. A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009 Antiviral Ther. 2010, 15, 853-859
4. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-06 influenza season. Morbidity Mortality Wkly. Rep. 2006, 55, 44-46.
5. Kolocouris, N.; Foscolos, G. B.; Kolocouris, A.; Marakos, P.; Pouli, N.; Fytas, G.; Ikeda, S.; De Clercq, E. Synthesis and antiviral activity evaluation of some aminoadamantane derivatives J. Med. Chem. 1994, 37, 2896-2902 (Pubitemid 24297806)
6. Kolocouris, A.; Spearpoint, P.; Martin, S. R.; Hay, A. J.; Lopez-Querol, M.; Sureda, F. X.; Padalko, E.; Neyts, J.; De Clercq, E. Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues Bioorg. Med. Chem. Lett. 2008, 18, 6156-6160
7. Stouffer, A. L.; Acharya, R.; Salom, D.; Levine, A. S.; Di Costanzo, L.; Soto, C. S.; Tereshko, V.; Nanda, V.; Stayrook, S.; DeGrado, W. F. Structural basis for the function and inhibition of an influenza virus proton channel Nature 2008, 451, 596-599 (Pubitemid 351186271)
8. Cady, S. D.; Schmidt-Rohr, K.; Wang, J.; Soto, C. S.; Degrado, W. F.; Hong, M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers Nature 2010, 463, 689-692
9. Cady, S. D.; Wang, J.; Wu, Y.; DeGrado, W. F.; Hong, M. Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy J. Am. Chem. Soc. 2011, 133, 4274-4284
10. Pielak, R. M.; Oxenoid, K.; Chou, J. J. Structural investigation of rimantadine inhibition of the AM2-BM2 chimera channel of influenza viruses Structure 2011, 19, 1655-1663
11. Hu, J.; Fu, R.; Cross, T. A. The chemical and dynamical influence of the anti-viral drug amantadine on the M2 proton channel transmembrane domain Biophys. J. 2007, 93, 276-283 (Pubitemid 47041672)
12. Wang, J.; Wu, Y.; Ma, C.; Fiorin, G.; Pinto, L. H.; Lamb, R. A.; Klein, M. L.; Degrado, W. F. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 1315-1320
13. Scholtissek, C.; Quack, G.; Klenk, H. D.; Webster, R. G. How to overcome resistance of influenza A viruses against adamantane derivatives Antiviral Res. 1998, 37, 83-95 (Pubitemid 28186299)
14. Kurtz, S.; Luo, G.; Hahnenberger, K. M.; Brooks, C.; Gecha, O.; Ingalls, K.; Numata, K.; Krystal, M. Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: identification of a novel inhibitor of influenza virus Antimicrob. Agents Chemother. 1995, 39, 2204-2209
15. Balannik, V.; Wang, J.; Ohigashi, Y.; Jing, X.; Magavern, E.; Lamb, R. A.; Degrado, W. F.; Pinto, L. H. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus Biochemistry 2009, 49, 696-708
16. Duque, M. D.; Ma, C.; Torres, E.; Wang, J.; Naesens, L.; Juarez-Jimenez, J.; Camps, P.; Luque, F. J.; DeGrado, W. F.; Lamb, R. A.; Pinto, L. H.; Vazquez, S. Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus J. Med. Chem. 2011, 54, 2646-2457
17. Wang, J.; Ma, C.; Fiorin, G.; Carnevale, V.; Wang, T.; Hu, F.; Lamb, R. A.; Pinto, L. H.; Hong, M.; Klein, M. L.; DeGrado, W. F. Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2 J. Am. Chem. Soc. 2011, 133, 12834-12841
18. 1,5]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant J. Med. Chem. 2013, 56, 9265-9274
19. Zhang, W. Heterodimers of histidine and amantadine as inhibitors for wild type and mutant M2 channels of influenza A Chin. J. Chem. 2010, 28, 1417-1423
20. Shibnev, V. A.; Garayev, T. M.; Finogenova, M. P.; Shevchenko, E. S.; Burtseva, E. I. New adamantane derivatives and ways of overcoming the resistance of influenza A viruses to rimantadine and amantadine Vopr. Virusol. 2011, 56, 36-39
21. Zhao, X.; Jie, Y.; Rosenberg, M. R.; Wan, J.; Zeng, S.; Cui, W.; Xiao, Y.; Li, Z.; Tu, Z.; Casarotto, M. G.; Hu, W. Design and synthesis of pinanamine derivatives as anti-influenza A M2 ion channel inhibitors Antiviral Res. 2012, 96, 91-99
22. Shibnev, V. A.; Garaev, T. M.; Finogenova, M. P.; Shevchenko, E. S.; Burtseva, E. I. New adamantane derivatives can overcome resistance of influenza A(H1N1)pdm2009 and A(H3N2) viruses to rimantadine Bull. Exp. Biol. Med. 2012, 153, 233-235
23. Torres, E.; Fernández, R.; Miquet, S. P.; Font-Bardia, M.; Vanderlinden, E.; Naesens, L.; Vázquez, S. Synthesis and anti-influenza A virus activity of 2,2-dialkylamantadines and related compounds ACS Med. Chem. Lett. 2012, 3, 1065-1069
24. Wang, J.; Ma, C.; Jo, H.; Canturk, B.; Fiorin, G.; Pinto, L. H.; Lamb, R. A.; Klein, M. L.; Degrado, W. F. Discovery of novel dual inhibitors of wild-type and the most prevalent drug-resistant mutant, S31N, of M2 proton channel from influenza A virus J. Med. Chem. 2013, 56, 2804-2812
25. Torres, E.; Duque, M. D.; Vanderlinden, E.; Ma, C.; Pinto, L. H.; Camps, P.; Froeyen, M.; Vazquez, S.; Naesens, L. Role of the viral hemagglutinin in the anti-influenza virus activity of newly synthesized polycyclic amine compounds Antiviral Res. 2013, 99, 281-291
26. Kalir, A.; Balderman, D. Org. Synth. 1981, 60, 104-107
27. Sasaki, T.; Eguchi, S.; Toi, N. Synthesis of adamantane derivatives. 47. Photochemical synthesis of 4-azahomoadamant-4-enes and further studies on their reactivity in some cycloadditions J. Org. Chem. 1979, 44, 3711-3715
28. Wang, J.; Denny, J.; Tian, C.; Kim, S.; Mo, Y.; Kovacs, F.; Song, Z.; Nishimura, K.; Gan, Z.; Fu, R.; Quine, J. R.; Cross, T. A. Imaging membrane protein helical wheels J. Magn. Reson. 2000, 144, 162-167
29. Hu, J.; Asbury, T.; Achuthan, S.; Li, C.; Bertram, R.; Quine, J. R.; Fu, R.; Cross, T. A. Backbone structure of the amantadine-blocked trans-membrane domain M2 proton channel from influenza A virus Biophys. J. 2007, 92, 4335-4343 (Pubitemid 46915327)
30. Li, C.; Qin, H.; Gao, F. P.; Cross, T. A. Solid-state NMR characterization of conformational plasticity within the transmembrane domain of the influenza A M2 proton channel Biochim. Biophys. Acta 2007, 1768, 3162-3170 (Pubitemid 350236087)
31. Chizhmakov, I. V.; Geraghty, F. M.; Ogden, D. C.; Hayhurst, A.; Antoniou, M.; Hay, A. J. Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells J. Physiol. 1996, 494, 329-336 (Pubitemid 26318773)
32. Balannik, V.; Carnevale, V.; Fiorin, G.; Levine, B. G.; Lamb, R. A.; Klein, M. L.; DeGrado, W. F.; L Pinto, L. H. Functional studies and modeling of pore-lining residue mutants of the influenza A virus M2 ion channel Biochemistry 2010, 49, 696-708
33. Appleyard, G. Amantadine-resistance as a genetic marker for influenza viruses J. Gen. Virol. 1977, 36, 249-255 (Pubitemid 8150866)
34. Oxford, J. S.; Potter, C. W.; Logan, I. S. Passage of influenza strains in the presence of aminoadamantane Ann. N.Y. Acad. Sci. 1970, 173, 300-313
35. Hayden, F. G.; Sperber, S. J.; Belshe, R. B.; Clover, R. D.; Hay, A. J.; Pyke, S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine Antimicrob. Agents Chemother. 1991, 35, 1741-1747
36. Hay, A. J.; Wolstenholme, A. J.; Skehel, J. J.; Smith, M. H. The molecular basis of the specific anti-influenza action of amantadine EMBO J. 1985, 4, 3021-3024
37. Gamblin, S. J.; Haire, L. F.; Russell, R. J.; Stevens, D. J.; Xiao, B.; Ha, Y.; Vasisht, N.; Steinhauer, D. A.; Daniels, R. S.; Elliot, A.; Wiley, D. C.; Skehel, J. J. The structure and receptor binding properties of the 1918 influenza hemagglutinin Science 2004, 303, 1838-1842 (Pubitemid 38374870)
38. Shibata, M.; Aoki, H.; Tsurumi, T.; Sugiura, Y.; Nishiyama, Y.; Suzuki, S.; Maeno, K. Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine J. Gen. Virol. 1983, 64, 1149-1156 (Pubitemid 13099395)
39. Dudleenamjil, E.; Lin, C. Y.; Dredge, D.; Murray, B. K.; Robison, R. A.; Johnson, F. B. Bovine parvovirus uses clathrin-mediated endocytosis for cell entry J. Gen. Virol. 2010, 91, 3032-3041
40. Kuehn, B. M. CDC: Use antivirals early, aggressively for H7N9 flu JAMA, J. Am. Med. Assoc. 2013, 309, 2086
41. Schmidtke, M.; Schnittler, U.; Jahn, B.; Dahse, H. M.; Stelzner, A. A rapid assay for evaluation of antiviral activity against coxsackievirus B3, influenza virus A, and herpes simplex virus type 1 J. Virol. Methods 2001, 95, 133-143 (Pubitemid 32493844)
42. Krumbholz, A.; Schmidtke, M.; Bergmann, S.; Motzke, S.; Bauer, K.; Stech, J.; Dürrwald, R.; Wutzler, P.; Zell, R. High prevalence of amantadine resistance among circulating European porcine influenza A viruses J. Gen. Virol. 2009, 90, 900-908
43. Hoffmann, E.; Stech, J.; Guan, Y.; Webster, R. G.; Perez, D. R. Universal primer set for the full-length amplification of all influenza A viruses Arch. Virol. 2001, 146, 2275-2289 (Pubitemid 34682391)
44. Kovacs, F. A.; Cross, T. A. Transmembrane four-helix bundle of influenza A M2 protein channel: structural implications from helix tilt and orientation Biophys. J. 1997, 73, 2511-2517 (Pubitemid 27471459)
45. Wu, C. H.; Ramamoorthy, A.; Opella, S. J. High-resolution heteronuclear dipolar solid-state NMR spectroscopy J. Magn. Reson. 1994, 109, 270-272
46. Fung, B. M.; Khitrin, A. K.; Ermolaev, K. An improved broadband decoupling sequence for liquid crystals and solids J. Magn. Reson. 2000, 142, 97-101
47. Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; Bax, A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes J. Biomol. NMR 1995, 6, 277-293